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Abstract
Insufficient sleep and circadian rhythm disturbances have been each associated with adverse 
cardiovascular outcomes in epidemiologic studies, but experimental evidence for a causal link is 
scarce. The present study compares the impact of circadian misalignment (CM) to circadian 
alignment (CA) on human autonomic function using a nonrandomized parallel group design to 
achieve the same total sleep time in both conditions. Following baseline assessments (three days 
with 10h bedtimes), 26 healthy young adults were assigned to sleep restriction (SR; eight 5h 
bedtimes) with either fixed nocturnal bedtimes (CA; n=13) or bedtimes delayed by 8.5h on 4 of 
the 8 days (CM; n=13). Daytime ambulatory blood pressure (BP) and heart rate (HR, CA: n=11, 
CM: n=10), and 24-hour urinary norepinephrine levels (NE, CA: n=13, CM: n=13) were assessed 
at baseline and the end of SR. Nocturnal HR and heart rate variability (HRV) were analyzed 
during sleep at baseline and during the 4th and 7th nights of SR (CA: n=8, CM: n=12). SR 
resulted in a significant increase in daytime HR in both groups, without changes in BP. SR 
increased 24-hour urinary NE in the CM group (30±4 vs. 21±2 μg), but not in the circadian 
alignment group (group×condition, p=0.005). In contrast to the lack of detectable impact of CM 
on daytime autonomic function, SR with CM elicited greater increases in nocturnal HR, as well as 
greater reductions in vagal indices of HRV, than SR without CM (group×condition, p<0.05). In 
conclusion, SR and CM both result in impaired autonomic function that could lead, under chronic 
conditions, to enhanced cardiovascular risk.
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INTRODUCTION
The proportion of short sleepers in the adult U.S. population has increased significantly over 
the past few decades.1 A recent review2 highlights that the majority of epidemiological 
studies report a significant association between short sleep and hypertension. A number of 
these epidemiological studies have been prospective in nature, and a recent meta-analysis of 
longitudinal cohort studies reported that short sleep was associated with increased risk for 
hypertension.3 In contrast, data from well-controlled laboratory studies, thus far, have failed 
to support a cause and effect relationship between short sleep and hypertension. Meier-Ewert 
et al.4 and Sauvet et al.5 found that 10 and 6 days, respectively of experimental sleep 
restriction did not change daytime arterial blood pressure (BP). Additionally, experimental 
sleep restriction has been shown to impair daytime heart rate (HR) or heart rate variability 
(HRV) in some,4, 6 but not all,5, 7 studies.
Circadian misalignment (CM) is a condition typically associated with sleep restriction8 and 
occurs when endogenous circadian rhythms are desynchronized from the sleep-wake and 
feeding cycles. During CM, a number of rhythms of autonomic activity and endocrine 
release remain locked to the master circadian pacemaker located in the suprachiasmatic 
nucleus (SCN) of the hypothalamus, while multiple circadian oscillators located in 
peripheral tissues, including cardiac tissue and vascular smooth muscle, are partly 
synchronized by the timings of activity, sleep and/or food intake.9 It is well recognized that 
shift work and jet lag are both associated with CM, but other factors such as chronotype, 
feeding habits, technological devices, and psychiatric health can influence CM.10 As such, 
the prevalence of acute, recurrent or chronic CM is growing 11 and this has been suggested 
to have adverse cardiovascular consequences. Forced desynchrony, the gold-standard 
laboratory approach to examine CM, has been shown to increase daytime BP in humans.8 
However, this protocol involves reductions in total sleep time and thus the role of sleep loss 
in causing the cardiovascular alterations could not be fully elucidated.8
The present study aims to determine the impact of CM on autonomic nervous system (ANS) 
control of cardiovascular function. To this effect, we designed a sleep restriction protocol 
comparing healthy adults under conditions of circadian alignment (CA) versus CM, keeping 
the amount of daily sleep restriction identical. We hypothesized that sleep restriction would 
impair autonomic function, and that these impairments would be potentiated by CM when 
compared to CA.
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The study complied with the Declaration of Helsinki, all participants signed a written 
informed consent and the Institutional Review Board of the University of Chicago approved 
the protocol (Figure 1).
Participants included 26 young healthy men (n=19) and women (n=7) aged 20–39 years who 
have been described in a previous article that focused on glucose metabolism.12 The current 
manuscript focuses on autonomic and cardiovascular outcomes that have not been reported. 
All subjects were free of endocrine, cardiovascular, psychiatric and sleep disorders. Other 
exclusion criteria included medication use, smoking, excessive alcohol (> 2 drinks/day) or 
caffeine consumption (> 300 mg caffeine/day), shift work or travelling across time zones 
during the past 2 months. Self-reported habitual sleep duration was 7.5h to 8.5h. Participants 
in each group were recruited from the community around the University of Chicago campus 
using the same advertisement materials. They were not pair-matched or group-matched. The 
CM and CA groups did not differ in sex distribution, age, or BMI.12
Prior to the study, participants underwent a full in-laboratory polysomnography to exclude 
sleep apnea (apnea/hypopnea index>5 events/hour) and periodic leg movement during sleep 
(>5 events/hour).13 Participants were asked to follow standardized schedules (23:00h–
07:00h bedtimes) for a week before the study. Compliance was verified using wrist activity 
recordings (Actiwatch, MiniMitter Inc.). In women, the study was initiated during the early 
follicular phase of the menstrual cycle.
The study followed a nonrandomized, parallel group design comparing two interventions, 
each involving approximately 2 weeks of hospitalization. Both interventions (Figure 1) 
consisted of three days with 10-hour bedtimes (22:00h–08:00h: BL1-BL3; baseline rested 
condition), followed by 8 days with 5-hour bedtimes (SR1-SR8) resulting in a total of 24 
hours of lost sleep opportunity over 8 days. Bedtimes were either always centered at 03:00h 
(00:30h–05:30h, CA) or delayed by 8.5 hours on 4 days (09:00h–14:00h on days SR2-SR3, 
SR5-SR6; CM). Participants abstained from caffeinated beverages throughout the protocol. 
On days BL3 and SR8, 24h blood sampling for hormonal and metabolic assessments was 
performed at 15- to 30-minute intervals (for more details, see Leproult et al.12).
Sleep
Sleep during each night was polygraphically recorded (Neurofax EEG-1100A, Nihon 
Kohden, Foothill Ranch, CA) using frontal, central and occipital electroencephalographic 
channels, electrooculograms, submental electromyogram, electrocardiogram, chest and 
abdominal belts. Sleep recordings were visually scored in 30-sec epochs in stages Wake, I, 
II, slow-wave sleep (SWS) and REM according to standardized criteria.14 Total sleep time 
was defined as the sum of the minutes of intra-sleep stages I, II, SWS and REM.
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Ambulatory BP and HR
Blood pressure and HR measurements were obtained from the non-dominant arm at BL3 
and SR8 while the subjects remained at bedrest. BP and HR were recorded at 15-minute 
intervals from 14:00h until 21:00h and again from 8:00h to 14:00h via an ambulatory 
monitoring device (Accutracker II, Suntech Medical Instruments, Morrisville, NC). The first 
hour of each measurement was not included in the analysis to eliminate possible artifacts 
related to the beginning of the recording (Figure 1). Each isolated measurement that 
corresponded to a peak or a drop greater than 15 (mmHg or bpm) over or below the previous 
and next measurements was considered to be a technical artifact and was interpolated. In five 
subjects, the ambulatory blood pressure monitoring device failed to record multiple and 
consecutive measurements over ≥2 hours time frame. As such, these five individuals were 
excluded from the repeated-measure analysis, resulting in a total of 21 subjects with 
complete daytime ambulatory BP (CA, n=11; CM, n=10). Mean arterial pressure (MAP) 
was estimated using the standard calculation of one-third pulse pressure plus diastolic 
pressure.15
Urinary Norepinephrine
Urine norepinephrine (NE) was obtained over 3 time intervals (15:00h–21:00h, 21:00h–
9:00h and 9:00h–15:00h) during BL3 and SR8 (Figure 1). Fractionated urinary NE was 
assayed using a high performance liquid chromatography with electrochemical detection 
system (Coulochem Electrode Array System (CEAS), ESA, Inc.). Twenty-four-hour NE 
excretion and urinary NE levels for the 3 time intervals normalized per hour were computed.
HRV during sleep
HRV analyses were performed during one baseline night (BL2) and two nights of nocturnal 
bedtime restriction (SR4 and SR7; Figure 1). In 3 participants, baseline HRV assessments 
were derived from night BL1 because recordings during BL2 were of poor quality (n=1 in 
CA and n=2 in CM).
HRV analyses focused on the first three cycles of sleep (i.e. approximately the first 5 hours 
of sleep). For each cycle, HRV analysis was performed on 5-minute periods during stage II, 
SWS and REM sleep. An experienced neurologist (DG), blinded to the intervention 
condition (i.e., CM vs CA), visually selected each 5-minute period to exclude portions of 
recording with breathing instabilities, arousals,16 body movements, ectopic beats and 
artifacts. To ensure a stationary signal,17 the same selection criteria were applied during the 
30-sec epoch preceding and the 30-sec epoch following each 5-minute period.
HR and HRV were quantified during each 5-minute interval to derive time and frequency 
domain indices (PRANA software; Phitools, Strasbourg, France). For each sleep stage, 
results of the analysis of the 5-minute periods in the three sleep cycles were averaged. The 
time domain index of HRV is reported as the square root of the mean of the squares of the 
successive differences between adjacent R-R intervals (RMSSD), which is strongly 
correlated with the parasympathetic modulation of HR.17 Spectral analysis of HRV was 
performed by Fast Fourier Transform, and spectral power was calculated in the high 
frequency band (HF; 0.15–0.40 Hz) reflecting mostly vagal activity and in the low frequency 
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band (LF: 0.04–0.14 Hz) reflecting a combination of vagal and sympathetic activities. 
Limitations associated with frequency domain analyses are acknowledged.18
Statistical Analysis
Results are expressed as mean (standard deviation) for normally distributed data, or as 
median (25th, 75th percentiles) for data not normally distributed. We maintained the use of 
SEM in figures to maximize legibility. Repeated measures ANOVA were performed 
including condition (baseline vs. day of sleep restriction) and time (time of day), when 
applicable, as the within-subject factors, and group (CA vs. CM) as the between-subject 
factor. During nocturnal HR and HRV analyses, each stage was analyzed independently. Age 
and BMI were included as covariates. Between-group differences in changes from baseline 
of HR and HRV indices were also analyzed using a generalized linear model for repeated 
measures. When not normally distributed, the variables were log-transformed to meet the 
requirements for linear model analysis. All statistical calculations were performed using 
JMP software (SAS Institute Inc., Cary, NC). Statistical significance was set at p < 0.05.
RESULTS
Participants
Demographics for the 26 participants have been previously reported.12 Daytime BP and HR 
were available for 21 participants, and nocturnal HR and HRV for 20 participants. There 
were no significant differences in demographic characteristics between the CA and CM 
groups in any of the analyses.
Polysomnography
The protocol was successful in achieving similar sleep durations in both the aligned and 
misaligned conditions as total sleep time during each night of the study (3 nights of baseline 
and 8 nights of sleep restriction) was nearly identical in the CM and CA groups, as 
previously reported.12 For the subset of 20 participants in whom we report nocturnal HR and 
HRV, total sleep time, as well as the amounts of stage II, SWS and REM sleep, were also 
similar in the two groups (see online Figure S1).
Daytime Ambulatory BP and HR
Figure 2 illustrates that sleep restriction significantly increased daytime HR from baseline by 
5–10 bpm above baseline in both CM and CA groups (condition: p<0.001). These clinically 
relevant increases in daytime HR were not different between CM and CA groups (condition 
× group: p=0.46). Sleep restriction did not alter daytime MAP in either CM or CA groups 
(condition: p=0.14; condition x group: p= 0.52). Similarly, mean systolic and diastolic BP 
during evening and morning hours were not affected by sleep restriction in either group 
(data shown in Table S1).
Daytime and Nocturnal Urinary NE
Baseline 24-hour NE levels were within the normal range for healthy adults (< 80 μg/24-
hour) in all subjects.19 Baseline NE values were higher in subjects exposed to CA (group: 
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p<0.01), and this difference was not explained by differences in demographic characteristics. 
Figure 3 (upper panel) illustrates that 24-hour urine NE increased significantly after 8 days 
of sleep restriction in subjects exposed to CM (baseline: 21±8 μg; SR: 30±13 μg; p=0.013), 
but not in participants exposed to sleep restriction alone (baseline: 39±15 μg; SR: 34±14 μg; 
p=0.26, condition x group: p= 0.009).
When urinary NE levels were examined during the 3 time intervals of urine collection, there 
was a significant group x condition interaction (p=0.005), and post-hoc analysis revealed 
that NE levels increased more during nocturnal and morning hours as compared to baseline 
in the CM group, while no significant changes in urinary NE were observed in the CA group 
(Figure 3, lower panels). Specifically, sleep restriction with CM increased urine NE by 
approximately 76% during the nighttime period (baseline: 0.6±0.3 μg/hr; intervention: 
0.9±0.4 μg/hr; p=0.047) and by approximately 78% during the morning period (baseline: 
1.1±0.5 μg/hr; intervention: 1.7±0.8 μg/hr; p=0.012).
Nocturnal HR and HRV
In the subset of participants in whom nocturnal HR and HRV could be analyzed, there were 
no significant group differences in sex distribution (CA: 3/8 women; CM: 4/12; p=0.85), 
BMI (CA: 23.1±2.4 kg/m2; CM: 22.1±2.5 kg/m2; p=0.19) and age (CA: 24.5±4.5 years; 
CM: 22.7±4.0 years; p=0.09). Nocturnal HR and HRV indices and respiratory frequency at 
baseline were not different between the two groups during all sleep stages (see online Table 
S2). Changes in respiratory frequencies during the intervention nights were comparable in 
the two groups in all sleep stages (group x condition: Stage II p=0.82; SWS p=0.28; REM 
p=0.51).
Figure 4 illustrates that during SWS, normally the most restorative state of sleep, sleep 
restriction increased HR, in both the CM and CA groups (condition: p=0.030), but these 
increases in HR were greater in the CM group (group × condition: p<0.001). During SWS, 
sleep restriction decreased RMSSD (condition: p<0.01) and increased LF/HF ratio 
(condition: p<0.01) in the CM group, but not in the CA group (group × condition: p=0.008 
and p=0.045, respectively).
Similarly, sleep restriction increased HR during stage II in both CM and CA groups 
(condition: p=0.013), and these increases in HR were greater in the CM group (group × 
condition: p= 0.016). Sleep restriction increased LF/HF ratio during stage II (condition: 
p<0.01) in the CM group, but not in the CA group (group × condition: p=0.045). Sleep 
restriction tended to decrease RMSSD during stage II in the CM group (p=0.049), but not in 
the CA group (group × condition: p=0.082). Sleep restriction increased LF/HF ratio 
(p<0.01) during REM sleep in the CM group, but not in the CA group (group × condition: 
p= 0.038). Sleep restriction, with or without CM, did not change HR during REM sleep 
(condition: p= 0.921; group × condition: p=0.303) or REM RMSSD (condition: p= 0.887; 
group × condition: p=0.301).
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This well-controlled laboratory study is the first to determine the impact of CM on 
autonomic and cardiovascular function in sleep restricted humans. Indeed, when controlling 
for the amount of sleep restriction, our data reveal three novel findings. First, sleep 
restriction with CM, but not with CA, significantly increased urinary NE and reduced 
nocturnal HRV. Second, sleep restriction with CM elicited greater increases in nocturnal HR 
when compared to sleep restriction alone. Third, these alterations in autonomic indices did 
not translate into an augmentation of arterial BP, suggesting that other compensatory 
mechanisms are engaged to offset the observed impairment in sympathetic and 
parasympathetic functions during sleep restriction with CM. Collectively, these findings 
demonstrate a clear adverse impact of CM on autonomic function in sleep-restricted healthy 
adults.
Several recent studies have suggested that CM can impair autonomic and cardiovascular 
function.20–22 Of particular interest, Scheer et al.8 utilized a forced desynchrony protocol to 
examine the impact of CM on autonomic and cardiovascular function. The protocol involved 
10 days of forced desynchrony between endogenous circadian cycles and the imposed sleep-
wake schedule. When participants slept and ate approximately 12 hours out of phase with 
their endogenous circadian rhythm, their BP was elevated during waking periods, while HR 
was unchanged. However, the authors report that total sleep time was reduced, and 
acknowledged that the role of this reduction of sleep duration in the observed cardiovascular 
alterations could not be fully determined.8 Accordingly, the present study used a novel 
protocol in which sleep was restricted to the same extent with or without CM to examine the 
impact of CM, in the presence of nearly identical levels of sleep loss. Our results reveal that 
this approach successfully increased sleep pressure, and yielded similar total sleep times 
throughout all baseline and sleep restriction nights in both the CM and CA groups. However, 
our findings do not demonstrate that an impact of CM could be detected in the absence of 
sleep loss.
Epidemiological studies have reported significant associations between sleep loss and 
hypertension.2 A recent meta-analysis of longitudinal epidemiological studies reports that 
short sleep is associated with increased risk for hypertension.3 Moreover, acute experimental 
models utilizing 24 to 88 consecutive hours of total sleep deprivation consistently report 
increases in arterial BP.4, 23–25 Taken together, these prospective epidemiological and acute 
total sleep deprivation studies hint towards a causal relationship between sleep loss and 
hypertension, but experimental data of well-controlled semi-chronic sleep restriction do not 
support this concept. Meier-Ewert et al.4 and Sauvet et al.5 both reported that experimental 
sleep restriction of, respectively, 10 and 6 days did not affect daytime arterial BP. Our 
findings advance this prior work in an important way. Indeed, these two previous studies 
obtained only a single time point “snapshot” of arterial BP, one using a 10-min period of 
calibrated Portapres recordings5 and the other using unspecified casual General Clinical 
Research Center (GCRC) BP measurements.4 In contrast, the present study utilized a 
carefully controlled ambulatory BP monitoring system providing BP values at 15-min 
intervals throughout waking hours. Our findings demonstrate unambiguously that one week 
of experimental bedtime restriction to 5h per night does not result in significant elevations of 
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arterial BP at any time of the waking period in healthy young adults, even when sleep loss is 
combined with CM, thus confirming and greatly extending the previous studies.4–5
There are several possible explanations for the discrepancies between the prospective 
epidemiological studies and the laboratory sleep restriction studies. First, studies of 
experimental sleep restriction, including our own, have ranged in duration from 7 to 10 days, 
while prospective epidemiological studies have ranged from 2–12 years.2 Second, 
participants in laboratory studies were young and healthy while epidemiologic studies 
enrolled a subject population with a wider range of demographics. Thirdly, the vast majority 
of epidemiological studies were based on self-reported sleep duration, which is not strongly 
correlated with objectively-defined sleep duration. Lastly, it is possible that the well-
controlled conditions of the laboratory studies eliminate effects of sleep restriction that 
could, under real life conditions, cause elevations in BP. For example, participants in our 
laboratory studies typically report low levels of stress on validated scales,6 while meeting 
professional and personal demands when being chronically sleep deprived may be much 
more stressful. In addition, in the laboratory, intake of caffeine, salt, and caloric-dense food 
is carefully controlled while, under real life conditions, insufficient sleep often results in 
increased caffeine, salt, and caloric intake that may in turn increase blood pressure.
Despite similar ambulatory BP responses to sleep restriction in CA and CM groups, our data 
reveal significant differences in several key autonomic variables between the 2 groups that 
may precede changes in ambulatory BP. Of particular interest, sleep restriction increased 
urinary NE levels only when combined with CM. NE baseline values were higher in subjects 
exposed to CA compared to those exposed to CM. However, all values were within the 
normal range for healthy adults 19 and the demographic characteristics of the two groups 
were similar. The difference in baseline NE levels therefore reflects random sampling within 
the wide physiologic range of basal NE levels. Of note, despite a wide inter-individual 
variability in 24h NE levels, intra-individual levels are relatively stable over time.26 
Moreover, it is worth noting that Faraut et al. 27 recently reported that one-night of sleep 
deprivation increased urinary NE from ~40 mcg/day to more than 70 mcg/day. Our CA 
group displayed a similar baseline value to that of Faraut et al. (i.e., 39 mdg/day); thus, we 
are confident that our subjects were well within the range of being able to demonstrate 
further increases in urinary NE with an adequate stressor (i.e., not a “ceiling” effect). We 
acknowledge that the urinary NE baseline value for the CM group was on the lower side of 
the normative range (i.e., 15 – 80 μg/24 hr),19 and thus we cannot rule out regression to the 
mean as an alternative explanation for the increase in NE levels in the CM group.
Urinary NE provides a reliable marker of sympathetic function that is highly dependent 
upon glomerular filtration rate and renal function.28 The sympathetic nervous system is 
highly specific and regionalized, thus we do not infer that sleep restriction with CM elicits a 
global increase of sympathetic activation. However, the increase of urinary NE after sleep 
restriction with CM suggests it may be valuable to utilize more invasive and regionally 
specific techniques such as microneurography and norepinephrine spillover to increase our 
understanding of the impact of sleep restriction and circadian dysfunction on sympathetic 
function.
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Consistent with prior work,4 sleep restriction increased daytime ambulatory HR. The present 
study advances this prior work by demonstrating that CM does not appear to exacerbate this 
tachycardia response to sleep restriction. However, in contrast to the daytime ambulatory 
HR, we observed a significant influence of CM on nocturnal HR and HRV responses to 
sleep restriction. During sleep, HRV analysis explores the integrity of ANS function in the 
absence of confounding factors such as physical activity and higher cortical functions. A 
reduction of HRV has been associated with an adverse prognosis in multiple cardiovascular 
diseases.17, 29 Previous studies that have explored the cardiovascular alterations associated 
with CM and sleep have primarily focused on assessments during daytime sleep when the 
circadian rhythm of ANS activity is in an opposite phase relative to nighttime sleep.21, 30 
These prior studies 21, 30 report that HR and LF:HF ratio were significantly increased during 
daytime sleep compared to nighttime sleep, suggesting that daytime sleep cannot provide the 
same cardiovascular restorative effects as nighttime sleep. In contrast, we investigated the 
cardiovascular consequences of sleep restriction with CM during the first re-aligned night 
after daytime sleep, when the behavioral sleep-wake cycle was identical to that of the CA 
group. We found that sleep restriction with CM was associated with higher HR and lower 
HRV during non-REM stages (i.e., SWS and Stage II) as compared to sleep restriction with 
CA. Given the importance of SWS and non-REM sleep in cardiovascular restoration,31 these 
findings suggest that recurrent or chronic circadian misalignment has adverse cardiovascular 
effects that are not readily corrected as soon as a normal daytime schedule is re-instated. The 
rate of recovery of nocturnal autonomous nervous system activity following abrupt shifts of 
the sleep-wake cycle needs further study to improve our understanding of the adverse 
cardiovascular consequences of shift work and design preventive strategies.
Morris et al.32 recently reported that 3 days of CM (12-h inversion of the behavioral and 
environmental cycle) without bedtime restriction elicited a reduction of daytime vagal 
indices of HRV, an increase in 24-h BP and inflammatory markers, but no changes in 24-h 
urinary NE excretion. The reduction in diurnal vagal cardiac control described by Morris et 
al.32 corroborates our findings from nighttime HRV analysis indicating a reduction in vagal 
activity in subjects exposed to CM. There is, however, a discrepancy between our findings 
and those of Morris et al.32 regarding BP and urinary NE responses to CM. The differences 
in the two experimental approaches (i.e., CM and CA with similar levels of sleep restriction 
vs. CM via 12-h inversion of the behavioral and environmental cycle without control for 
sleep duration) likely explain these divergent findings. Indeed, Morris et al.32 report that 
sleep duration was different between their CM and CA groups. It is important to note that 
while these in-laboratory studies are well-controlled, they are still relatively short in duration 
(i.e., 3–8 days) compared to real-life CM. It remains possible that longer duration CM, with 
or without sleep restriction, would negatively impact both urinary NE and ambulatory BP. 
Nevertheless, when taken together these two studies complement one another in suggesting 
the possibility of an increased cardiovascular risk in subjects exposed to CM, and suggest 
that there may be a complex interaction between CM and sleep restriction that warrants 
further investigation.
We acknowledge some limitations in the present study. First, as previously reported,12 the 
two interventions could not be conducted simultaneously for logistic reasons and therefore 
assignment of the participants to the CA or CM group was not randomized in a traditional 
Grimaldi et al. Page 9













fashion. However, the same advertisement materials were used for both groups and the 
subjects were not aware that an alternate intervention existed. It is possible that the lack of 
randomization contributed to the differences in NE baseline values between the two groups, 
but we believe this is unlikely since baseline differences were not observed for other 
autonomic variables or for metabolic variables. Second, we introduced age and BMI as 
covariates in our analyses despite our limited sample size, and therefore there is a potential 
for statistical over-fitting. However, when we excluded age and BMI from our statistical 
models, the primary findings remained unchanged.
In conclusion, the present study reports that sleep restriction with CM, as typically occurs in 
shift workers, results in altered autonomic function during wakefulness and sleep. In 
particular, sleep restriction with CM increases norepinephrine secretion and reduces cardiac 
vagal modulation which could, under chronic conditions, lead to an increased risk of 
cardiovascular disease.
Perspectives
Our findings are of importance to a number of conditions associated with sleep restriction 
with CM. For example, insufficient sleep is particularly common in shift workers, who 
represent 15 to 30% of the working population.33–35 Irrespective of the schedule, shift work 
is typically associated with chronic CM. Prospective studies report adverse cardiovascular 
outcomes in shift workers,19–22 and a recent meta-analysis of cross-sectional studies found 
that shift work is associated with an increased risk for myocardial infarction and all coronary 
events.36 In healthy subjects, the highest vagal influence on HR occurs during NREM sleep, 
together with the highest feedback contribution of the baroreflex,37–38 consistent with a 
cardio-restorative role of NREM sleep. The results of this non randomized parallel group 
study suggest that shift workers might not benefit from the restorative cardiovascular effects 
of aligned nights of sleep following a shift work rotation, and may therefore not readily 
recover from their irregular sleep-wake pattern. Our findings hence suggest a mechanistic 
link between the reduction of cardiac vagal modulation during sleep found in our subjects 
exposed to CM, and the increased risk to develop adverse cardiac events observed in shift 
workers.
Evidence from rodent models has revealed that there are distinct phase relationships between 
rhythms of circadian gene expression in cardiac tissue, the liver and the SCN, and that these 
phase relationships need to be stable to achieve optimal cardio-metabolic function at each 
time of day.39–40 In addition to shift work, other factors such as jet lag, chronotype, feeding 
cycles, technological devices, and psychiatric health can influence CM.9 Therefore, the 
autonomic dysfunction reported during sleep restriction with CM in the present study is 
relevant to an increasingly wide-range of individuals.
Supplementary Material
Refer to Web version on PubMed Central for supplementary material.
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1) What is New?
• Sleep restriction with circadian misalignment increases urinary norepinephrine 
and nocturnal heart rate, and reduces nocturnal heart rate variability, when 
compared to sleep restriction with circadian alignment.
• These altered autonomic indices do not translate into an augmentation of 
ambulatory daytime arterial blood pressure.
2) What is Relevant?
• Sleep loss and circadian misalignment are common among shift workers. Our 
results suggest that shift workers might not benefit from the restorative 
cardiovascular effects of nighttime sleep following a shift work rotation.
Summary
This nonrandomized study is the first to determine the impact of CM on autonomic and 
cardiovascular function in sleep restricted humans. Our results demonstrate altered 
autonomic function during wakefulness and sleep, which under chronic conditions could 
lead to an increased risk of cardiovascular disease.
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Schematic representation of the study protocol.
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Mean (±SEM) heart rate (upper panels) and mean arterial pressure (lower panels) measured 
every 15 minutes during daytime hours at baseline (black) and after eight days of sleep 
restriction (red). Heart rate, but not mean arterial blood pressure, significantly increased after 
sleep restriction in both the circadian alignment and misalignment groups (condition, p < 
0.001; condition x group, p= 0.46).
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Upper panel: mean (+SEM) 24h norepinephrine urine concentrations at baseline and at 8th 
day of sleep restriction (group x condition: p= 0.009). Lower panels: mean (± SEM) 
norepinephrine levels during daytime and nighttime periods (normalized per hour) (group x 
condition: p=0.005). * p ≤ 0.05 vs. corresponding baseline.
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Changes from baseline (± SEM) in heart rate (group x condition p= 0.016), root mean 
square of sequential differences of RR-intervals (RMSSD) (group x condition p= 0.008), and 
low frequency to high frequency (LF/HF) ratio (group x condition p= 0.045) in the 4th and 
7th night of sleep restriction (SR4 and SR7) during slow wave sleep. bpm= beats per minute; 
a.u.= arbitrary units. * p ≤ 0.05 vs. corresponding baseline.
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